论文部分内容阅读
目的观察三维适形放疗的肿瘤患者接受重组人血管内皮抑制素(YH-16),其血压、凝血、纤溶系统相关指标的变化,探讨YH-16在联合三维适形放疗时可能导致高血压、出血、血栓等不良反应。方法30例患者随机分为两组,对照组(n=15)接受三维适形放疗,用药组(n=15)接受三维适形放疗的同时,每日静脉YH-1615mg滴注,连续14d。YH-16使用前1d及使用后3、7、14d空腹采集外周静脉血,用全自动血凝仪检测凝血酶原时间(PT)、纤维蛋白原(Fib)、部分凝血活酶时间(APTT)、凝血酶时间(TT)和D-二聚体(D-D)。两组患者在治疗前及治疗过程中每2d早晚各测2次血压。结果用药组患者的TT和Fib在7、14d时较对照组患者差异有统计学意义(P<0.05),其他检查指标两组患者差异无统计学意义(P>0.05),两组患者血压无明显变化(P>0.05)。结论YH-16对于肿瘤患者凝血功能具有一定影响。
Objective To observe the changes of related parameters of blood pressure, blood coagulation and fibrinolysis in patients with tumors of three-dimensional conformal radiotherapy receiving recombinant human endostatin (YH-16) and to explore the possible role of YH-16 in the combination of three-dimensional conformal radiotherapy , Bleeding, thrombosis and other adverse reactions. Methods Thirty patients were randomly divided into two groups. The control group (n = 15) underwent three-dimensional conformal radiotherapy. The rats in the treatment group received n = 15 three-dimensional conformal radiotherapy and the intravenous drip of YH-1615mg for 14 days. Peripheral venous blood was collected on 1d and 1, 7 and 14 d before YH-16, and the contents of PT, Fib, APTT, , Thrombin time (TT) and D-dimer (DD). Two groups of patients before and during treatment every 2d morning and evening each measured 2 blood pressure. Results Compared with the control group, the TT and Fib levels of the patients in the medication group were significantly different at 7 and 14 days (P <0.05). There was no significant difference in the other indexes between the two groups (P> 0.05). The blood pressure Significant changes (P> 0.05). Conclusion YH-16 has certain influence on the coagulation function of tumor patients.